Compare TXO & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TXO | ACHV |
|---|---|---|
| Founded | 2012 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 781.2M | 726.5M |
| IPO Year | 2022 | 2018 |
| Metric | TXO | ACHV |
|---|---|---|
| Price | $14.28 | $7.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $20.50 | $14.67 |
| AVG Volume (30 Days) | 156.5K | ★ 1.4M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 13.57% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $401,012,000.00 | N/A |
| Revenue This Year | $17.21 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 41.80 | N/A |
| 52 Week Low | $10.12 | $2.62 |
| 52 Week High | $15.58 | $8.64 |
| Indicator | TXO | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 42.70 | 48.75 |
| Support Level | $13.66 | $7.01 |
| Resistance Level | $14.61 | $8.63 |
| Average True Range (ATR) | 0.38 | 0.39 |
| MACD | -0.16 | -0.04 |
| Stochastic Oscillator | 0.00 | 41.84 |
TXO Partners LP is focused on the acquisition, development, optimization, and exploitation of oil, natural gas, and natural gas liquid reserves in North America. Its operations focus on enhancing the development and operation of producing properties through its concentration on efficiency and optimizing exploitation of current wells.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.